Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease

BACKGROUND: Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at insoluble fibrils and slowed clinical decline in an 18-month phase 2 proof-of-concept study (Study 201; ClinicalTrials.gov NCT01767311) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhadda, Shobha, Kanekiyo, Michio, Li, David, Swanson, Chad J., Irizarry, Michael, Berry, Scott, Kramer, Lynn D., Berry, Donald A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733166/
https://www.ncbi.nlm.nih.gov/pubmed/36482412
http://dx.doi.org/10.1186/s13195-022-01129-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733166/
https://www.ncbi.nlm.nih.gov/pubmed/36482412
http://dx.doi.org/10.1186/s13195-022-01129-x

Ejemplares similares